European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global: Annual Meeting 2025 Highlights

ESCMID Global is the annual congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (formerly ECCMID).

ESCMID Global 2025 took place in Vienna, Austria between April 11-15, 2025.
The analyst remotely attended a number of scientific sessions where key therapies were featured, the contents of which were analyzed to create this ESCMID Global 2025 Highlights report.

Scope

Indications, companies, and therapies discussed:

Gram-negative bacterial infections

• Shionogi - Fetroja (cefiderocol)

Genital herpes

• Assembly Biosciences - ABI-5366

Respiratory syncytial virus (RSV)

• GSK - Arexvy (RSVPreF3 OA)

Gonorrhea

• GSK - Blujepa (gepotidacin)

Lyme borreliosis

• Valneva/Pfizer - VLA15

Mpox

• Moderna - mRNA-1769

Cholera

• Harvard Medical School - PanChol

Group B streptococcus

• MinervaX - MVX0006

Reasons to Buy

This powerpoint-based deliverable provides analysis on key presentations from the conference, and what they mean for your strategy, covering disease areas such as Lyme borreliosis, RSV, mpox, gonorrhea, cholera, and more.

Inside the report you’ll find:

• Emerging trends in prophylactic or therapeutic strategies for the management of viral, and bacterial infections
• Insights into the disease areas and key sponsors that took precedence at the conference
• Key takeaways from headline sessions and late-breaking data
• Clinical and commercial implications of notable presentations